121 Intramural Biomedical Projects in Rare Diseases (PIBER) Support Platforms for Research into Rare Diseases (PITER) Management Office Scientific Director.

Slides:



Advertisements
Similar presentations
© Fraunhofer ISI Seite 1 Smoke screens and sacred fires: Translational research and grand challenges in European biomedicine. Etienne Vignola-Gagné Fraunhofer.
Advertisements

SPANISH ASSOCIATION OF ATAXIA PATIENTS FEDAES  In 1998, we generated the ing list of Hispataxia and the webpage.  In 2000, we contacted researchers.
Michel Goldman, Executive Director Innovative Medicines Initiative (IMI)
Welcome to the NIHR Peter Knight, Deputy Director Research Contracting, Information Intelligence and Stakeholder Engagement NIHR Trainees Meeting Leeds.
Educational modules for innovational drug development researchers M.V.Lomonosov Moscow State University - Faculty of bioengineering and bioinformatics.
Dr. Joan Lluis Vives-Corrons Head of ENERCA project Head of the Red Cell Pathology Unit Hospital Clínic - IDIBAPS of Barcelona “ Rare Diseases a model.
Update on a recently launched European R&D endeavour: The Innovative Medicines Initiative (IMI) FERS meeting Brussels, 7 th April 2008.
Vision in Scientific and Medical Publishing | Future Science Group SCHOLARLY PUBLISHING AT THE SPEED OF SCIENCE LISA PATERSON.
Who am I? A Brief Bio PhD with John Schrader at The Biomedical Research Centre (UBC) Undergrad at Simon Fraser University Genetics: 3 summers in a Drosophila.
1 The UK Opportunity: what is experimental medicine? UNLOCK YOUR GLOBAL BUSINESS POTENTIAL Pre- clinical develop- ment Phase I Phase II Phase III Product.
Governing internal access to data and materials in large research consortia: A mechanism for facilitating translation? Dr Michael Morrison University of.
Pharmacogenomics: Implications for CNS Drug Development in the 21st Century Challenges for Development & Approval – Patient & Funding Agency Perspective.
Improving Animal and Human Health by Accelerating Veterinary Centered Entrepreneurship.
This document arises from the project InNerMeD-I-Network which has received funding from the European Union, in the framework of the Health Programme INHERITED.
Service System for Management and Sharing of Scientific Data in Medicine Depei Liu, Ph.D. Chinese Academy of Medical Sciences.
The involvement of patients in Health Technology Assessment Andrzej Rys Director Health and Consumers Directorate-General Brussels 18 May 2010.
Science, research and developmentEuropean Commission Chile-EC S&T Agreement Brussels, 24 September 2002 Life Sciences, Genomics and Biotechnology for Health.
ACCELERATING CLINICAL AND TRANSLATIONAL RESEARCH
THANK YOU!. Regional Adviser, Noncommunicable Diseases, WHO/EMRO Dr Ibtihal Fadhil.
Dr Stewart Hay, CEO | | (03) www.therapeuticinnovation.com.au.
BioSciencs Foro November 8th, New York Joaquin Guinea Chairman of BIOMADRID (
Innovation Pathway AHSN Stakeholder Event Russ Watkins Assistant Director – Business Innovation & Improvement Newcastle Hospitals.
A project implemented by the HTSPE consortium This project is funded by the European Union SECURITY AND CITIZENSHIP.
Dr. José M. Millán, PhD Deputy Director of CIBERER Universitary Hospital La Fe, Valencia, Spain Barriers and Challenges in Rare Diseases Research Centre.
Partnering with Federal Labs: A Panel Discussion FLC Mid-Atlantic Region Annual Meeting October 24, 2007.
UWA, COVS and LEI COVS is effectively the academic arm of LEI through which competitive research grants are managed and to which academic appointments.
Safe and Effective Medicine for Children Daring to be Rare, BIOTECanada Panel 2015 CADTH Symposium Saskatoon, April
The Innovative Medicines Initiative (IMI) High level the IMI Concept, Strategic Research Agenda and Call topics Eva Lindgren.
Steph Garfield-Birkbeck Assistant Director NIHR Evaluation Trials and Studies Coordinating Centre, University of Southampton.
SHAAMS-Social Acceleration -State of the art in Lebanon- Presented by Krystel Khalil Berytech.
September 13, 2007SGH&M2B International&Training Workshop What does the European Technology Platform “Innovative Medicines initiative” offer? Vitalijs.
European Platform of Women Scientists The European Platform of Women Scientists - The Voice of Women Scientists in EU Research Policy Raising the Voice.
A Model for Translating Research into Practice in the United States - Mexico Border Region Howard J. Eng, MS, DrPH Director, Southwest Border Rural Health.
1970s Functional Genetics From … Functional Genomics … to … Evolution of.
María Amor Barros del Río Gender as content in research in Horizon 2020 GENDER AS CONTENT IN RESEARCH IN HORIZON 2020 CAPACITY BUILDING WORKSHOP FOR RESEARCHERS.
EURORDIS Eurordis Position on Research Priorities for Rare Diseases.
Biomedical Engineering at the Centre for Preclinical Research and Technology Contemporary medicine is challenged to seek methods for delaying and alleviating.
○ Area Yonsei Biomedical Science and Technology Initiative (YBSTI)
Dr Godfrey Grech University of Malta
Human Embryos and Gene-editing Research and regulation in China Prof. Zhihong Xu, Peking University & Chinese Academy of Sciences.
Research Funding Opportunity & Scientific Capacity Building in Developing Countries By Dina R. Andersson 1.
Why Write A Grant? Elaine M. Hylek, MD, MPH Professor of Medicine Associate Director, Education and Training Division BU CTSI Section of General Internal.
Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.
South Region Conference & AGM 13 th June 2003 “BIFM Research & Knowledge” Peter Cordy, Chairman of the BIFM Research, Information & Knowledge Committee.
Joint Action on Addressing Chronic Diseases and Healthy Ageing Across the Life-Cycle (JA-CHRODIS) An Overview Teresa Chavarría National Institute of Health.
An initiative of the International Rare Diseases Research Consortium-IRDiRC Spanish Rare Diseases Registries Research Network - SpainRDR
Session 4. Evaluation of publicly funded research development and innovation: The Integral Monitoring and Evaluation System (SISE) Alfonso Beltrán García-Echániz.
Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.
European Patients’ Academy on Therapeutic Innovation Translational Medicine: An introduction.
The 7th Framework Programme for Research: Strategy of international cooperation activities Robert Burmanjer Head of Unit, “International Scientific Cooperation.
National Information Day Greece 23 July 2015 Funding priorities under the work plan 2015.
Institutional Development Award (IDeA) Program – Infrastructure for Clinical and Translational Research (IDeA-CTR) J. Rafael Gorospe M.D. Ph.D. Medical.
Wellcome Trust / Glaxo Smith Kline Translational Medicine Training Programme at Imperial College Dr Waljit Dhillo.
BioMedical Cluster New opportunities for innovators and investors with Bio-Medical Cluster of Skolkovo Foundation Innovation in Medical Technologies Conference,
M O N T E N E G R O Negotiating Team for the Accession of Montenegro to the European Union Working Group for Chapter 28 – Consumer and Health Protection.
The opportunities and challenges of sharing genomics data with the pharmaceutical industry Shahid Hanif, Head of Health Data & Outcomes, ABPI DNA digest.
A capacity building programme for patient representatives
Community Advocacy & Education to End Stigmatizing HIV/TB Language
Action: BM0806 Recent Advances in Histamine Receptor H4R Research
OMICS Journals are welcoming Submissions
Use of Induced Pluripotent Stem Cells in Dermatological Research
Overview of Clinical & Translational Penn
Dr Peter Groves MD FRCP Consultant Cardiologist
Publishers of Quality Research
Quality and Process Improvement Program (QPIP)
COST and COST Actions Participation of Georgian researchers
Trial Funding and Engagement: The NIH Sponsored CTSA Program
EUnetHTA Assembly May 2018.
Clinical research in Southampton is a partnership between University Hospital Southampton NHS Foundation Trust and the University of Southampton, combining.
Center for Clinical and Translational Science
Presentation transcript:

121 Intramural Biomedical Projects in Rare Diseases (PIBER) Support Platforms for Research into Rare Diseases (PITER) Management Office Scientific Director Governing Board Permanent Commission External Advisory Scientific Committee Management Committee () (Coordinators) Associated Clinical Groups Intramural Projects and Support Platforms Organization Chart of the CIBERER

2 seven Research Programmes CIBERER units are organized into seven Research Programmes: Cooperative research in the field of rare diseases Reseach Programmes Genetic Medicine 16 research groups Inherited Metabolic Medicine 11 research groups Mitochondrial Medicine 8 research groups Pediatric and Developmental Medicine 8 research groups Neurosensorial Pathology 7 research groups Endocrine Medicine 4 research groups Inherited Cancer and Related Syndromes 6 research groups

3 60 Research Groups 29 Consorted Institutions 7 Research Programmes Cooperative Research in Rare Diseases. The centre encloses clinical and basic researchers promoting Cooperative Research in Rare Diseases. innovative network structure : It is a Centre with an innovative network structure : offers opportunities of research actions and public-private collaboration. Internal Structure of CIBERER The knowledge generated is translated from the laboratory to clinical practice Translational Research Translational Research

4 increasing the research capacity of its scientific groups knowledge about Rare Diseases During its 5 years of existence, the CIBERER has allowed increasing the research capacity of its scientific groups and has increased the knowledge about Rare Diseases. CIBERER Programmes have: Cooperation Joined and increased the Cooperation between basic and clinical units Research Increased the Research on Rare Diseases Participation Fostered the Participation of groups in the CIBERER’s programmes Institutional Relations Established Institutional Relations PromotedDisseminated Promoted and Disseminated the activities of groups International Cooperation Fostered the International Cooperation opportunities of groups Network core facilities Cooperative research in the field of rare diseases BIER BioInformatica de Enfermedades Raras

5 Cooperation with the Spanish Biotech Stakeholders Association (ASEBIO) Collaboration with specific preclinical research actors Agreement with Medina Foundation: non-profit public–private partnership between Merck Sharp and Dohme and public institutions focused on the discovery of new compounds and innovative therapies for unmet medical needs Examples of intramural cooperative research projects Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Raya et al. CIBERER Units 710 & 745. Nature May 31 Transplantation of histocompatible allogeneic epidermal stem cells: Development of an effective clinical resource for patients with dystrophic epidermolysis bullosa. INTRA/08/714,1. Gene therapy in Dyskeratosis congenita INTRA/08/757,1. CIBERER Units 757 & 710 Evaluation of the immune response and oxidative stress in patients affected by Gaucher disease subjected to different forms of therapeutic treatment. INTRA/08/ CIBERER Units 752 & 719 CIBERER member of Innovative Medicaments working group CIBERER´s therapeutic research

6 The approach is to establish scientific collaborations with experts from others academic research groups, biotech and pharmaceutical companies interested in testing their compounds and their panels of target screens in specific rare diseases models. CIBERER experimental models network resources: 91 animal models for the study of rare diseases: Mouse, Zebrafish, Drosophila, Medaka, C. elegans. 59 cells models for the study of rare diseases: HeLa, 3T3, SH-S5SY neuroblastoma cells, fibroblasts, COS cells, lymphoblast cells, astrocytes… Experimental models in rare diseases: towards preclinical research Example of animal models: McArdle disease ( Pygm) X-linked adrenoleukodystrophy ( Abcd1 ) Charcot-Marie-Tooth type 4A (Gdap1) Retinitis pigmentosa (Cerkl) Down syndrome (Dyrk1a, others) Lafora disease (malin, laforine) Etc. Example of animal models: McArdle disease ( Pygm) X-linked adrenoleukodystrophy ( Abcd1 ) Charcot-Marie-Tooth type 4A (Gdap1) Retinitis pigmentosa (Cerkl) Down syndrome (Dyrk1a, others) Lafora disease (malin, laforine) Etc.

: an increase of the scientific collaboration and productivity by the CIBERER groups Evolution of intramural collaboration - CIBERER and

8 Intramural collaboration – CIBERER : an increase of the scientific collaboration and productivity by the CIBERER groups

9 Collaborative network of CIBERER groups with other Spanish institutions (240) Collaborative network of CIBERER groups with other international institutions (742) : an increase of the scientific collaboration and productivity by the CIBERER groups

10 Outcomes: increase on the number and quality of papers in RD Publications output between Documents Original Article Biography2 Correction Editorial Material Letter Meeting Abstract Proceedings Paper7972 Review Cited % cited/total81,474,773,384,870,681,2 Total

11 Evolution of the papers distribution of CIBERER groups based on JIF (Journal Impact Factor) parameters Outcomes: increase on the number and quality of papers in RD

12 Go raibh maith agat Thank you More Information: (+34) “A model of Cooperative Research on Rare Diseases”